
Release date: 2026-03-06 16:02:13 Article From: Lucius Laos Recommended: 8
Osimertinib is a targeted therapy used to treat specific types of non-small cell lung cancer. Its price in China varies due to factors such as dosage form, purchasing channel, and medical insurance policies. Out-of-pocket costs after insurance reimbursement can be significantly reduced. The following is a detailed breakdown:
Brand-name (Imported) drugs: Prices are relatively high and vary based on regional policies.
Generic (Domestic or Overseas) drugs: Prices are generally lower, but it is essential to purchase them through legitimate channels to ensure safety and efficacy.
Patients who meet the specific indications for the drug (e.g., advanced lung cancer with the EGFR T790M mutation) may be eligible for reimbursement rates ranging from 30% to 80%. The exact rate is determined by local medical insurance policies.
Some regions include Osimertinib in their outpatient special disease reimbursement programs, further reducing the financial burden on patients.
Purchasing medication through hospital pharmacies or designated pharmacies allows for insurance reimbursement. The out-of-pocket expense depends on the individual's insurance type (e.g., employee insurance, resident insurance).
Purchasing through non-insurance channels (e.g., some private hospitals or overseas agents) can be more expensive and carries potential risks.
Certain pharmaceutical companies or charitable organizations offer medication assistance programs. Eligible patients may apply for "buy-and-give" programs or cost reductions, such as receiving subsequent medication doses for free after purchasing a specified treatment course.
Some commercial medical insurance policies may cover costs not included in basic medical insurance. It is crucial to verify the policy's terms regarding coverage for targeted therapies in advance.
Some provinces or cities provide additional subsidies for cancer patients. It is advisable to consult the local Healthcare Security Administration or community health service centers for more information.
Lucius Pharmaceuticals Osimertinib must be prescribed based on genetic test results (e.g., confirming an EGFR mutation). Do not purchase or adjust the dosage on your own.
During treatment, regular monitoring of liver function, electrocardiograms (ECGs), and other tests is necessary. Be aware of potential drug interactions (e.g., combining with non-steroidal anti-inflammatory drugs may increase the risk of side effects).
Common side effects include rash, diarrhea, and interstitial lung disease. Seek immediate medical attention if severe discomfort occurs.
After a confirmed diagnosis, prioritize genetic testing to determine if you meet the indications for Osimertinib.
Consult your primary physician or the hospital's insurance office to understand the local reimbursement policies and application procedures for patient assistance programs.
Obtain the medication through legitimate channels. Avoid using generic versions or products from agents with unknown origins.
For more detailed information on costs or treatment plans, it is recommended to visit the oncology or respiratory department of a top-tier hospital to develop a personalized treatment plan based on your individual circumstances.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:1532025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3942024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:1462025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:1662025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:1492025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:1772025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:1612025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:1552025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: